Company HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Advanced Medical Equipment & Technology

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Medical Diagnostic & Testing Equipment

Market Closed - OTC Markets Other stock markets 03:52:59 2024-04-19 pm EDT			5-day change	1st Jan Change
0.0025 ^USD	+66.67%		+66.67%	+92.31%

2023	Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	CI
2023	Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	CI

HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Number of employees: 54

USD in Million	2021	Weight	2022	Weight	Delta
Consumables 49.3 %	4	42.5 %	3	49.3 %	-17.07%
Research Use Only Sample Processing 40.8 %	4	41.4 %	3	40.8 %	-29.56%
Instruments 9.6 %	1	15.6 %	1	9.6 %	-56.00%
Custom Research Use Only Assay Design 0.3 %	0	0.5 %	0	0.3 %	-58.63%

USD in Million	2021	Weight	2022	Weight	Delta
United States 65.1 %	6	69.0 %	4	65.1 %	-32.61%
Europe 34.5 %	3	31.0 %	2	34.5 %	-20.38%
Foreign 0.4 %	0	0.0 %	0	0.4 %	-

Managers	Title	Age	Since
John Lubniewski CEO	Chief Executive Officer	60	11-03-31
Shaun McMeans DFI	Director of Finance/CFO	62	12-01-31
Laura L. Godlewski ADM	Chief Administrative Officer	45	14-12-31

Members of the board	Title	Age	Since
Lee Roy McCracken BRD	Director/Board Member	66	15-10-26
Christopher Kiritsy BRD	Director/Board Member	59	22-01-26
Ann Hanham CHM	Chairman	71	16-08-28
Thomas Dubensky BRD	Director/Board Member	66	22-08-17
John Lubniewski CEO	Chief Executive Officer	60	11-03-31
Michelle Griffin BRD	Director/Board Member	58	18-08-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,214,233	2,169,854 ( 98.00 %)	0	98.00 %

Name	Equities	%	Valuation
AULT ALLIANCE, INC. 1.769 %	39,167	1.769 %	78 $
John Lubniewski 0.0532 %	1,177	0.0532 %	2 $
Shaun McMeans 0.0397 %	880	0.0397 %	2 $
Byron Lawson 0.0227 %	502	0.0227 %	1 $
Stephen Barat 0.0190 %	421	0.0190 %	1 $
Laura L. Godlewski 0.0185 %	409	0.0185 %	1 $
Donnie Hardison 0.003116 %	69	0.003116 %	0 $
Ann Hanham 0.001806 %	40	0.001806 %	0 $
Lee Roy McCracken 0.001219 %	27	0.001219 %	0 $
Michelle Griffin 0.000587 %	13	0.000587 %	0 $

HTG Molecular Diagnostics, Inc.

3430 East Global Loop

85706-5009, Tucson

+877 289 2615

http://www.htgmolecular.com

address HTG Molecular Diagnostics, Inc.(HTGMQ)

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Advanced Medical Equipment & Technology

Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
HTG MOLECULAR DIAGNOSTICS, INC.	+92.31%	3.32K
QUIDELORTHO CORPORATION	-46.92%	2.56B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+7.27%	1.66B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-15.17%	1.45B
BIOTAGE AB	+18.55%	1.2B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-15.69%	978M
CONTEC MEDICAL SYSTEMS CO.,LTD	-24.43%	875M
REVENIO GROUP OYJ	-9.20%	698M
VAREX IMAGING CORPORATION	-17.12%	687M
CELLAVISION AB	+5.90%	480M

Medical Diagnostic & Testing Equipment